ClinicalTrials.gg
Status unknownNCT03293017Updated Nov 4, 2021

Baclofen in Managing Acute Alcohol Withdrawal

A Phase 4 interventional study of Diazepam 10 MG and Baclofen 30mg in Alcohol Use Disorder and Alcohol Withdrawal, sponsored by Universitair Ziekenhuis Brussel. Status unknown at 1 site in Belgium. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Universitair Ziekenhuis Brussel · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2016, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing baclofen in Alcoholism — none open to participants now, none under way, none of them phase 3. Baclofen · Alcoholism.

Planned enrollment
8th of 17
90 · median 86
Started
2016
with 2 others
Phase 4
4 of 17
none open now
Registered
17th of 17
by date

Among the 17 studies testing baclofen in Alcoholism, this one is the 8th largest by planned enrollment, is one of 3 that started in 2016, is one of 4 in phase 4, and was the 17th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 17 studies testing baclofen in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About baclofen

Baclofen: first FDA approval 1977 (LIORESAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing baclofen in Alcoholism as a file.
02

Study summary

The study goal is to investigate whether administration of oral baclofen forms an adequate treatment option in the management of acute alcohol withdrawal. The investigators will compare placebo with doses of baclofen 30 and 60 milligram per day (mg/day) in a randomized controlled trial including patients receiving symptom triggered diazepam.

Read the detailed description

The conducted study will be randomized and single-blind (patients). After signing informed consent, the participants will be randomized in one of three groups: - placebo - baclofen 30 mg/day - baclofen 60 mg/day. The participants will be given a first administration after which the participant can receive Clinical Institute Withdrawal Assessment (CIWA-ar) score triggered diazepam, frequently assessed for at least 7 days. The primary outcome measure is the number of participants who received additional diazepam during these 7 days. The secondary outcome measure is the amount of diazepam received per group.

03

Conditions studied

  • Alcohol Use Disorder
  • Alcohol Withdrawal

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be an inpatient at the Psychiatry unit at UZBrussel at time of study enrollment.
  • Be able to sign .
  • Be male/female aged 18-60
  • Primary diagnosis of alcohol use disorder.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and breastfeeding.
  • Benzodiazepine use of more than the equivalent of diazepam 25 mg /day.
  • Psychosis, confusion and acute mania.
  • Parkinson's disease.
  • Use of tricyclic antidepressants.
  • Use of opioids.
  • Known baclofen or benzodiazepine sensitivity or allergy.
  • Unable to take oral medication.
  • epidermal growth factor receptor (EGFR) \< 60 (blood samples are routinely performed at intake).
  • Prior diagnosis of epilepsy.
  • Lactose intolerance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Baclofen 30 mg/day

    baclofen 30 mg/day

    Drug: Diazepam 10 MG · Drug: Baclofen 30mg

  • Experimental
    Baclofen 60 mg/day

    Drug: Diazepam 10 MG · Drug: Baclofen 60mg

  • Placebo comparator
    Placebo

    Drug: Diazepam 10 MG

Interventions

  • If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.

  • Baclofen 30 mg/day given over three gifts daily

  • Baclofen 60 mg/day given over three gifts daily

06

What researchers measure

Primary outcomes

  1. Need for additional diazepam

    Amount of patients who lack the need of additional diazepam during 7-day alcohol withdrawal

    Time frame: Measured 7 days after the start of alcohol withdrawal

Secondary outcomes

  1. Dosage of additional diazepam needed

    The difference between the total dosages of additional diazepam needed between the three study arms

    Time frame: Measured 7 days after the start of alcohol withdrawal

07

Study locations

1 of 1 sites recruiting
  • University Hospital Brussels
    Brussels, 1090, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2016 (actual). Primary completion is estimated for Feb 2022, 72 months after the start.

Of 24 phase 4 interventional studies under Alcoholism, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 83. This study's planned 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2017
First posted
Sep 26, 2017
StartActual
Feb 1, 2016
Primary completionEst.
Feb 1, 2022
CompletionEst.
Feb 1, 2022
Last update
Nov 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03293017
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Feb 1, 2016
Primary completion
Feb 1, 2022 (estimated)
Completion
Feb 1, 2022 (estimated)
Last update
Nov 4, 2021

Study contacts

Cleo L Crunelle, PhD
Contact
nacstudie@gmail.com
Sami Jegham, MD
Contact
Frieda Matthys, PhD
principal investigator · Universitair Ziekenhuis Brussel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baclofen

Start the discussion